tert-butyl 2,2,3,3,5,5,6,6-octadeutero-4-hydroxypiperidine-1-carboxylate | 1523576-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 2,2,3,3,5,5,6,6-octadeutero-4-hydroxypiperidine-1-carboxylate
• 英文别名: Tert-butyl 2,2,3,3,5,5,6,6-octadeuterio-4-hydroxypiperidine-1-carboxylate
• CAS: 1523576-39-7
• 化学式: C₁₀H₁₉NO₃
• 分子量: 209.202
• InChiKey: PWQLFIKTGRINFF-DUSUNJSHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS
  申请人：CONCERT PHARMACEUTICALS, INC.

  公开号：US20140005211A1

  公开（公告）日：2014-01-02

  This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
• FLUORO-DERIVATIVES OF PYRAZOLE-SUBSTITUTED AMINO-HETEROARYL COMPOUNDS
  申请人：CONCERT PHARMACEUTICALS, INC.

  公开号：US20150299170A1

  公开（公告）日：2015-10-22

  This invention relates to novel fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
• Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US20150366853A1

  公开（公告）日：2015-12-24

  This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
• US9145390B2
  申请人：——

  公开号：US9145390B2

  公开（公告）日：2015-09-29
• US9707218B2
  申请人：——

  公开号：US9707218B2

  公开（公告）日：2017-07-18